Clinical trial

A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy

NCT07777861

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-03-18

PhasePHASE2

Study timeline

Study start (actual)2026-03-18Date precision: day

Registry last updated2026-08-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Primary Open-Angle Glaucomaunresolved

Optic Nerve Injuryunresolved

Interventions

G01 Eye Drops 100μg/mlDRUG

G01 Eye Drops 200μg/mlDRUG

Placebo of G01 Eye DropsDRUG

Sponsors & collaborators

Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.lead sponsor

Mapped research locations

BeijingBeijing Municipality, China3 GuangzhouGuangdong, China1 HangzhouZhejiang, China1 ChangshaHunan, China1 TianjinTianjin Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07777861 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.